SweetValueLab
Write for us

CRISPR Therapeutics AG — Intrinsic Value & Fair Price

CRSP
NASDAQHealthcareBiotechnologyCIK 0001674416crisprtx.comAbout CRSP
Quant grade ?D
Last close · Oct 30, 202651.42−2.84 (−5.23%)

Valuation models

price $51.42 · as of Nov 2, 2026
EV/Revenue · peersused19.85 – 20.3219.90158% overvaluedWall St. consensus target—60.0014% belowCost of capital (WACC)—10.89%—

EV/Revenue · peers leads because DCF · Perpetuity growth · 5y could not lead: the cash-flow gate is shut (an operating loss, or three years of free cash flow summing below zero); P/E · peers does not describe this kind of business; EV/EBITDA · peers could not run on the filed statements. How the headline model is chosen. The price is 158% above the model value: the models see only the filed business, and a company priced on businesses with no revenue line yet is better taken apart, as Tesla is.

engine build:07a9d3f952ed
Model value · EV/Revenue · peers
19.90
CRISPR Therapeutics closed at $51.42 — overvalued by 158% vs model.
19.85the model's range20.32

EV/Revenue · peers leads because DCF · Perpetuity growth · 5y could not lead: the cash-flow gate is shut (an operating loss, or three years of free cash flow summing below zero); P/E · peers does not describe this kind of business; EV/EBITDA · peers could not run on the filed statements. From its peers' median EV/Revenue.

Other models
—
Wall St. target
60.00 14% below
Above model, 1y
0 of 0 days

How it is valued

Valued asLoss-Making
Revenue declining (~-90% recent)Decelerated from ~37% 5y CAGRCurrently unprofitableHighly cyclical earningsNegative free cash flow
What growth the price implies: the reverse DCF

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.